NHS study will pick apart mental illness with data science
Volunteers with schizophrenia, bipolar, and depression will take part in an NHS study that will use genetic and health data to find new therapies.
Newsletters and Deep Dive digital magazine
Volunteers with schizophrenia, bipolar, and depression will take part in an NHS study that will use genetic and health data to find new therapies.
Editor-in-chief Jonah Comstock sat down with pharmaphorum web editor Nicole Raleigh to discuss JPM2026.
Armed with new data, Compass wants to talk to the FDA about filing its psilocybin therapy COMP360 for approval in treatment-resistant depression.
Roche has appointed leading Australian cancer researcher Mark Dawson to lead its pRED R&D division, as the company prepares for a steep patent cliff.
Helus' psychedelic derived from ayahuasca, a brew used in shamanistic rituals in South America, has shown promise as a treatment for depression.
Editor's Picks
Newsletters and Deep Dive
digital magazine